Encouragingly, results from a recent phase Ib trial of oral HSP90 inhibitor TAS-116 showed a manageable safety profile and anti-tumour activity combined with nivolumab for treating colorectal cancer and other solid tumours 42. This evidence concerns the gene HSP90AA1 and colorectal cancer.